SCHEMBL2373205

SCHEMBL2373205

CNc1nc2ccccc2o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.61
RAB9A P51151 10/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
PKM P14618 3/20 0.61
GAA P10253 3/20 0.61
NPSR1 Q6W5P4 2/20 0.61
ALDH1A1 P00352 1/20 0.61
ELANE P08246 2/20 0.58
MAPT P10636 4/20 0.57
TP53 P04637 3/20 0.53
LMNA P02545 2/20 0.53
ALOX15 P16050 1/20 0.53
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HSP90AA1 P07900 1/20 0.50
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
SCD O00767 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL6805001 0.91 NPC1 (0.54) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL14549324 0.84 NPC1 (0.58) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL15022003 0.83 RAB9A (0.78) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL20195816 0.79 NPC1 (0.61) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL28637996 0.79 NPC1 (0.61) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL1163272 0.79 NPC1 (0.61) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL7434169 0.79 NPC1 (0.61) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL11451768 0.79 ELANE (0.61) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL18013094 0.79 NPC1 (0.56) NPC1RAB9ASMN1; SMN2PKMGAA
SCHEMBL3953148 0.79 ELANE (0.61) NPC1RAB9ASMN1; SMN2PKMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0712403-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-09-10 EP claimed
EP-0712403-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1996-05-22 EP claimed
WO-1995004735-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-02-16 WO claimed
US-4242495-A COATINGS, MOLDINGS, FOAMS THE FIRESTONE TIRE & RUBBER COMPANY (US) 1980-12-30 US claimed
EP-4257587-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2023-10-11 EP disclosed
US-20230203048-A1 SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-06-29 US disclosed
US-20230076435-A1 MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2023-03-09 US disclosed
EP-4053110-A1 MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2022-09-07 EP disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 US disclosed
US-10945996-B2 Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) 2021-03-16 US disclosed
WO-2021032209-A1 ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF 四川海思科制药有限公司 2021-02-25 WO disclosed
EP-3392242-B1 NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME LG CHEMICAL LTD (KR) 2021-02-24 EP disclosed
WO-2000047577-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2000-08-17 WO disclosed
CN-1040211-C Matrix metalloprotease inhibitors SYNTEX INC (US) 1998-10-14 CN disclosed
EP-0712403-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-09-10 EP disclosed
CN-1132511-A Matrix metalloprotease inhibitors SYNTEX A INC (US) 1996-10-02 CN disclosed
EP-0712403-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1996-05-22 EP disclosed
WO-1995004735-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-02-16 WO disclosed
CN-1062138-A The synergy of HIV reverse transcriptase inhibitors MERCK & CO INC (US) 1992-06-24 CN disclosed
US-4242495-A COATINGS, MOLDINGS, FOAMS THE FIRESTONE TIRE & RUBBER COMPANY (US) 1980-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230076435-A1 MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF GRM4, GRM5, GRIA4 NPC1 2716/4885RAB9A 533/4885SMN1; SMN2 2186/4885
US-20230203048-A1 SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, PKD1 NPC1 184/4885RAB9A 2264/4885SMN1; SMN2 2615/4885
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof ATG7, SQSTM1, BECN1 NPC1 231/4885RAB9A 130/4885SMN1; SMN2 4684/4885
US-10945996-B2 Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis CASP3, SI, PYCARD NPC1 1750/4885RAB9A 4497/4885SMN1; SMN2 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.